Administration of ervogastat to pregnant rats during organogenesis reduced fetal weight and caused higher incidences of bent bones in fetuses that were shown to resolve by postnatal day 28 and were therefore considered to be transient variations secondary to developmental delay. There were no effects on female rat fertility or rabbit embryo-fetal development. Fertility and developmental toxicity studies with ervogastat were conducted in female rats and rabbits. DGAT2 is a key enzyme in triglyceride synthesis in tissues and in regulating energy metabolism. Ervogastat (PF-06865571) is a small molecule diacylglycerol acyltransferase 2 (DGAT2) inhibitor being developed for the oral treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis.
0 kommentar(er)
